Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review

Stephen D Lawn, Stephen D Lawn

Abstract

Detection of Mycobacterium tuberculosis antigens in urine is attractive as a potential means of diagnosing tuberculosis (TB) regardless of the anatomical site of disease. The most promising candidate antigen is the cell wall lipopolysaccharide antigen lipoarabinomannan (LAM), which has been used to develop commercially available enzyme-linked immunosorbent assays. Although highly variable diagnostic accuracy has been observed in different clinical populations, it is now clear that this assay has useful sensitivity for diagnosis of HIV-associated TB in patients with advanced immunodeficiency and low CD4 cell counts. Thus, this assay is particularly useful when selectively used among patients enrolling in antiretroviral treatment services or in HIV-infected patients requiring admission to hospital medical wards. These are the very patients who have the highest mortality risk and who stand to gain the most from rapid diagnosis, permitting immediate initiation of TB treatment. A recently developed low-cost, lateral-flow (urine 'dip-stick') format of the assay provides a result within 30 minutes and is potentially a major step forward as it can be used at the point-of-care, making the possibility of immediate diagnosis and treatment a reality. This paper discusses the likely utility of this point-of-care assay and how it might best be used in combination with other diagnostic assays for TB. The many further research studies that are needed on this assay are described. Consideration is particularly given to potential reasons for the variable specificity observed in existing field evaluations of LAM ELISAs. Whether this might be related to the assay itself or to the challenges associated with study design is discussed.

Figures

Figure 1
Figure 1
Cartoon showing the basic structure of mycobacterial lipoarabinomannan (LAM) and its three main domains. (i) The glycophospholipid anchor binds the molecule to the plasma membrane of the organism. (ii) The mannan core is attached to this and is highly conserved across mycobacterial species. (iii) The variable branching arabinan side chains and the variable mannose capping of these side chains gives rise to the diversity of LAM molecules.
Figure 2
Figure 2
Graph showing the sensitivity of a commercially available enzyme-linked immunosorbent assay (ELISA) to detect lipoarabinomannan (LAM) within urine samples to diagnose tuberculosis (TB) in a cohort of patients accessing antiretroviral treatment (ART) in a South African township. The sensitivity (%) of sputum microscopy and the LAM ELISA are shown individually and combined (either positive) compared with a gold standard of automated liquid culture of two sputum samples. Data are stratified by CD4 cell count (cells/μL) and show that the sensitivity of the LAM ELISA was substantially greater in the patients with the lowest CD4 cell counts. Figure reproduced from Lawn et al. 2011 [5] and data originally from Lawn et al. 2009 [31].
Figure 3
Figure 3
Photograph of a Determine TB-LAM test strip showing the sample pad to which 60 μL of the test urine is applied. After 25–35 minutes of incubation at room temperature, the control band is checked and the sample test result is read. Reading may be facilitated by comparison to the reference card. The presence of a band in the sample window of similar or greater intensity to the weakest positive on the reference card indicates the presence of lipoarabinomannan (LAM) in the urine.
Figure 4
Figure 4
Graph showing the diagnostic sensitivity for sputum culture-positive tuberculosis using the Determine TB-LAM assay for lipoarabinomannan (LAM) when used alone or in combination with other diagnostics, including sputum smear microscopy (smear) and Xpert MTB/RIF (Xpert). Data are stratified by CD4 cell count (cells/μL) and show that the sensitivity of the LAM was substantially greater in the patients with the lowest CD4 cell counts. There was important incremental sensitivity when microscopy and Determine TB-LAM were combined and this was similar to the sensitivity of Xpert in patients with the lowest CD4 cell counts.

References

    1. Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011;378:57–72. doi: 10.1016/S0140-6736(10)62173-3.
    1. World Health Organization. Global tuberculosis control 2011. Accessed on 21.12.11 at:
    1. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS. 2009;4:325–333. doi: 10.1097/COH.0b013e32832c7d61.
    1. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis. 2009;9:173–184. doi: 10.1016/S1473-3099(09)70043-X.
    1. Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis. 2011;204(Suppl 4):S1159–S1167. doi: 10.1093/infdis/jir411.
    1. McNerney R, Daley P. Towards a point-of-care test for active tuberculosis: obstacles and opportunities. Nat Rev Microbiol. 2011;9:204–213. doi: 10.1038/nrmicro2521.
    1. Kashino SS, Pollock N, Napolitano DR, Rodrigues V, Campos-Neto A. Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules. Clin Exp Immunol. 2008;153:56–62. doi: 10.1111/j.1365-2249.2008.03672.x.
    1. Choudhry V, Saxena RK. Detection of Mycobacterium tuberculosis antigens in urinary proteins of tuberculosis patients. Eur J Clin Microbiol Infect Dis. 2002;21:1–5. doi: 10.1007/s10096-001-0651-7.
    1. Achkar JM, Lawn SD, Moosa MY, Wright CA, Kasprowicz VO. Adjunctive Tests for Diagnosis of Tuberculosis: Serology, ELISPOT for Site-Specific Lymphocytes, Urinary Lipoarabinomannan, String Test, and Fine Needle Aspiration. J Infect Dis. 2011;204(Suppl 4):S1130–S1141. doi: 10.1093/infdis/jir450.
    1. Minion J, Leung E, Talbot E, Dheda K, Pai M, Menzies D. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur Respir J. 2011;38:1398–1405. doi: 10.1183/09031936.00025711.
    1. Peter J, Green C, Hoelscher M, Mwaba P, Zumla A, Dheda K. Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin Pulm Med. 2010;16:262–270. doi: 10.1097/MCP.0b013e328337f23a.
    1. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012;12:201–209. doi: 10.1016/S1473-3099(11)70251-1.
    1. Peter JG, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, Kraus S, Binder A, Meldau R, Hardy A, Dheda K. Diagnostic accuracy of a urine LAM strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J. 2012.
    1. Briken V, Porcelli SA, Besra GS, Kremer L. Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol Microbiol. 2004;53:391–403. doi: 10.1111/j.1365-2958.2004.04183.x.
    1. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb) 2003;83:91–97. doi: 10.1016/S1472-9792(02)00089-6.
    1. Hunter SW, Gaylord H, Brennan PJ. Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli. J Biol Chem. 1986;261:12345–12351.
    1. Strohmeier GR, Fenton MJ. Roles of lipoarabinomannan in the pathogenesis of tuberculosis. Microbes Infect. 1999;1:709–717. doi: 10.1016/S1286-4579(99)80072-0.
    1. Venisse A. Berjeaud JM, Chaurand P, Gilleron M. Puzo G: Structural features of lipoarabinomannan from Mycobacterium bovis BCG. Determination of molecular mass by laser desorption mass spectrometry. J Biol Chem. 1993;268:12401–12411.
    1. Sada E, Aguilar D, Torres M, Herrera T. Detection of lipoarabinomannan as a diagnostic test for tuberculosis. J Clin Microbiol. 1992;30:2415–2418.
    1. Shah M, Martinson NA, Chaisson RE, Martin DJ, Variava E, Dorman SE. Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis. J Clin Microbiol. 2010;48:2972–2974. doi: 10.1128/JCM.00363-10.
    1. Hall CL, Hardwicke J. Low molecular weight proteinuria. Annu Rev Med. 1979;30:199–211. doi: 10.1146/annurev.me.30.020179.001215.
    1. Tessema TA, Bjune G, Hamasur B, Svenson S, Syre H, Bjorvatn B. Circulating antibodies to lipoarabinomannan in relation to sputum microscopy, clinical features and urinary anti-lipoarabinomannan detection in pulmonary tuberculosis. Scand J Infect Dis. 2002;34:97–103. doi: 10.1080/00365540110077263.
    1. Reither K, Saathoff E, Jung J, Minja LT, Kroidl I, Saad E, Huggett JF, Ntinginya EN, Maganga L, Maboko L. et al.Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis. BMC Infect Dis. 2009;9:141. doi: 10.1186/1471-2334-9-141.
    1. Dheda K, Davids V, Lenders L, Roberts T, Meldau R, Ling D, Brunet L, van Zyl SR, Peter J, Green C. et al.Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS One. 2010;5:e9848. doi: 10.1371/journal.pone.0009848.
    1. Wood R, Racow K, Bekker LG, Middelkoop K, Vogt M, Kreiswirth BN, Lawn SD. Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria. BMC Infect Dis. 2012;12:47. doi: 10.1186/1471-2334-12-47.
    1. Lawn SD, Kerkhoff AD, Vogt M, Ghebrekristos Y, Whitelaw A, Wood R. Characteristics and Early Outcomes of Patients With Xpert MTB/RIF-Negative Pulmonary Tuberculosis Diagnosed During Screening Before Antiretroviral Therapy. Clin Infect Dis. 2012;54:1071–1079. doi: 10.1093/cid/cir1039.
    1. Pereira Arias-Bouda LM, Nguyen LN, Ho LM, Kuijper S, Jansen HM, Kolk AH. Development of antigen detection assay for diagnosis of tuberculosis using sputum samples. J Clin Microbiol. 2000;38:2278–2283.
    1. Hamasur B, Bruchfeld J, Haile M, Pawlowski A, Bjorvatn B, Kallenius G, Svenson SB. Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine. J Microbiol Methods. 2001;45:41–52. doi: 10.1016/S0167-7012(01)00239-1.
    1. Tessema TA, Hamasur B, Bjun G, Svenson S, Bjorvatn B. Diagnostic evaluation of urinary lipoarabinomannan at an Ethiopian tuberculosis centre. Scand J Infect Dis. 2001;33:279–284. doi: 10.1080/003655401300077306.
    1. Boehme C, Molokova E, Minja F, Geis S, Loscher T, Maboko L, Koulchin V, Hoelscher M. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans R Soc Trop Med Hyg. 2005;99:893–900. doi: 10.1016/j.trstmh.2005.04.014.
    1. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS. 2009;23:1875–1880. doi: 10.1097/QAD.0b013e32832e05c8.
    1. Mutetwa R, Boehme C, Dimairo M, Bandason T, Munyati SS, Mangwanya D, Mungofa S, Butterworth AE, Mason PR, Corbett EL. Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients. Int J Tuberc Lung Dis. 2009;13:1253–1259.
    1. Daley P, Michael JS, Hmar P, Latha A, Chordia P, Mathai D, John KR, Pai M. Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study. Int J Tuberc Lung Dis. 2009;13:989–995.
    1. Shah M, Variava E, Holmes CB, Coppin A, Golub JE, McCallum J, Wong M, Luke B, Martin DJ, Chaisson RE. et al.Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting. J Acquir Immune Defic Syndr. 2009;52:145–151. doi: 10.1097/QAI.0b013e3181b98430.
    1. Gounder CR, Kufa T, Wada NI, Mngomezulu V, Charalambous S, Hanifa Y, Fielding K, Grant A, Dorman S, Chaisson RE. et al.Diagnostic Accuracy of a Urine Lipoarabinomannan Enzyme-Linked Immunosorbent Assay for Screening Ambulatory HIV-Infected Persons for TB. Future Microbiol. 2011;6:1067–1082. doi: 10.2217/fmb.11.84.
    1. Lawn SD, Nicol MP. Xpert(R) MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol. 2011;6:1067–1082. doi: 10.2217/fmb.11.84.
    1. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R. et al.Rapid Molecular Detection of Tuberculosis and Rifampin Resistance. N Engl J Med. 2010;363:1005–1015. doi: 10.1056/NEJMoa0907847.
    1. Dawson R, Masuka P, Edwards DJ, Bateman ED, Bekker LG, Wood R, Lawn SD. Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. Int J Tuberc Lung Dis. 2010;14:52–58.
    1. Lawn SD, Kerkhoff AD, Wood R. Location of Xpert MTB/RIF in centralised laboratories in South Africa undermines potential impact. Int J Tuberc Lung Dis 2012. p. s701.
    1. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS. 2010;5:18–26. doi: 10.1097/COH.0b013e328333850f.
    1. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897–1908. doi: 10.1097/QAD.0b013e32830007cd.
    1. Lawn SD, Ayles H, Egwaga S, Williams B, Mukadi YD. Santos Filho ED, Godfrey-Faussett P, Granich RM, Harries AD: Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. Int J Tuberc Lung Dis. 2011;15:287–295.
    1. Monkongdee P, McCarthy KD, Cain KP, Tasaneeyapan T, Nguyen HD, Nguyen TN, Nguyen TB, Teeratakulpisarn N, Udomsantisuk N, Heilig C. et al.Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am J Respir Crit Care Med. 2009;180:903–908. doi: 10.1164/rccm.200905-0692OC.
    1. Lawn SD, Kerkhoff AD, Pahlana P, Vogt M, Wood R. Incremental diagnostic yield of TB from sputum induction during screening of HIV patients before ART. Int J Tuberc Lung Dis 2012; in press
    1. Hillemann D, Rusch-Gerdes S, Boehme C, Richter E. Rapid Molecular Detection of Extrapulmonary Tuberculosis by the Automated GeneXpert MTB/RIF System. J Clin Microbiol. 2011;49:1202–1205. doi: 10.1128/JCM.02268-10.
    1. Ligthelm LJ, Nicol MP, Hoek KG, Jacobson R, van Helden PD, Marais BJ, Warren RM, Wright CA. Xpert MTB/RIF for rapid diagnosis of tuberculous lymphadenitis from fine-needle-aspiration biopsy specimens. J Clin Microbiol. 2011;49:3967–3970. doi: 10.1128/JCM.01310-11.
    1. Kadival GV, Mazarelo TB, Chaparas SD. Sensitivity and specificity of enzyme-linked immunosorbent assay in the detection of antigen in tuberculous meningitis cerebrospinal fluids. J Clin Microbiol. 1986;23:901–904.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever